154 related articles for article (PubMed ID: 38319515)
1. Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery.
Ando Y; Dbouk M; Blackford AL; Yoshida T; Saba H; Abou Diwan E; Yoshida K; Sokoll L; Eshleman JR; Burkhart R; He J; Goggins M
Ann Surg Oncol; 2024 May; 31(5):2902-2912. PubMed ID: 38319515
[TBL] [Abstract][Full Text] [Related]
2. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer.
Ando Y; Dbouk M; Yoshida T; Saba H; Abou Diwan E; Yoshida K; Dbouk A; Blackford AL; Lin MT; Lennon AM; Burkhart RA; He J; Sokoll L; Eshleman JR; Canto MI; Goggins M
J Clin Oncol; 2024 Jun; 42(18):2196-2206. PubMed ID: 38457748
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges.
Dbouk M; Abe T; Koi C; Ando Y; Saba H; Abou Diwan E; MacGregor-Das A; Blackford AL; Mocci E; Beierl K; Dbouk A; He J; Burkhart R; Lennon AM; Sokoll L; Canto MI; Eshleman JR; Goggins M
Clin Cancer Res; 2023 Oct; 29(20):4178-4185. PubMed ID: 37566230
[TBL] [Abstract][Full Text] [Related]
4. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
Abe T; Koi C; Kohi S; Song KB; Tamura K; Macgregor-Das A; Kitaoka N; Chuidian M; Ford M; Dbouk M; Borges M; He J; Burkhart R; Wolfgang CL; Klein AP; Eshleman JR; Hruban RH; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2020 May; 18(5):1161-1169.e5. PubMed ID: 31676359
[TBL] [Abstract][Full Text] [Related]
5. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
6. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
7. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
9. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
11. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma.
Newhook TE; Vreeland TJ; Griffin JF; Tidwell RSS; Prakash LR; Koay EJ; Ludmir EB; Smaglo BG; Pant S; Overman M; Wolff RA; Ikoma N; Maxwell J; Kim MP; Lee JE; Katz MHG; Tzeng CD
Ann Surg; 2023 Mar; 277(3):484-490. PubMed ID: 36649067
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
13. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first.
DiPeri TP; Newhook TE; Prakash LR; Ikoma N; Maxwell JE; Kim MP; Lee JE; Katz MHG; Tzeng CD
J Surg Oncol; 2022 Nov; 126(6):1021-1027. PubMed ID: 35726394
[TBL] [Abstract][Full Text] [Related]
14. Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection.
Xu J; Lyu S; Zhao Y; Zhang X; Liu Z; Zhao X; He Q
Technol Cancer Res Treat; 2022; 21():15330338221078438. PubMed ID: 35138217
[No Abstract] [Full Text] [Related]
15. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
[TBL] [Abstract][Full Text] [Related]
16. Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma.
Nurmi AM; Mustonen H; Haglund C; Seppänen H
Oncology; 2021; 99(11):686-698. PubMed ID: 34412062
[TBL] [Abstract][Full Text] [Related]
17. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
18. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy.
Yang HK; Park MS; Han K; Eom G; Chung YE; Choi JY; Bang S; Kang CM; Seong J; Kim MJ
Cancer Res Treat; 2024 Jan; 56(1):247-258. PubMed ID: 37605535
[TBL] [Abstract][Full Text] [Related]
19. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
20. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pancreatic ductal adenocarcinoma.
Moon D; Kim H; Han Y; Byun Y; Choi Y; Kang J; Kwon W; Jang JY
J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1133-1141. PubMed ID: 33063453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
